Viking Therapeutics, Inc. (VKTX)
NASDAQ: VKTX · Real-Time Price · USD
26.79
-2.43 (-8.33%)
At close: Nov 16, 2026, 4:00 PM EST
26.78
0.00 (-0.02%)
After-hours: Nov 16, 2026, 4:04 PM EST

Viking Therapeutics Stock Forecast

Stock Price Forecast

According to 21 analysts polled by S&P Global, Viking Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $95.32. The average 1-year stock price forecast is 255.87% higher than the current stock price, while the lowest is $34 (+26.94%) and the highest is $125 (+366.68%).

Price Target: $95.32 (+255.87%)
Analyst Consensus: Strong Buy

Price Target

Chart
TargetLowAverageMedianHigh
Price$34$95.32$95$125
Change+26.94%+255.87%+254.68%+366.68%

Analyst Ratings

The average analyst rating for Viking Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Chart
RatingJun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Strong Buy131313131414
Buy555555
Hold222222
Sell000000
Strong Sell000000
Total202020202121

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
Morgan Stanley
Morgan Stanley
Buy
Reiterates
$95
BuyReiterates$95+254.68%Nov 16, 2026
H.C. Wainwright
H.C. Wainwright
Buy
Reiterates
$102
BuyReiterates$102+280.81%Nov 16, 2026
Maxim Group
Maxim Group
Buy
Reiterates
$70
BuyReiterates$70+161.34%Oct 30, 2026
Canaccord Genuity
Canaccord Genuity
Buy
Maintains
$106 → $118
BuyMaintains$106 → $118+340.55%Oct 30, 2026
B. Riley Securities
B. Riley Securities
Buy
Maintains
$85
BuyMaintains$85+217.34%Oct 29, 2026
More Analyst Ratings

Financial Forecast

Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-5.31
from -3.19
EPS Next Year
-5.21
from -5.31
Fiscal YearFY 2021FY 2022FY 2023FY 2024FY 2025FY 2026
Period EndingDec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026
Revenue
------
Operating Income
-55.68M-70.36M-100.83M-150.92M-393.34M-655.83M
Net Income
-54.99M-68.87M-85.90M-109.96M-359.64M-641.94M
EPS
-----3.19-5.31
Free Cash Flow
-----696.72M-579.63M
No. Analysts
-----17
EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue202620272028
Highn/a
Avgn/a
Lown/a

Revenue Growth

Revenue Growth20272028
High-
Avg-
Low-

EPS Forecast

EPS202620272028
High-4.58
Avg-5.31
Low-5.66

EPS Growth

EPS Growth202620272028
High-
Avg-
Low-